Proposal:Prescription Drug Monitoring Act of 2019

This proposal is archived and closed to further debate. It was introduced in the 116th Congress, which has concluded, and the bill was not enacted into law.

Bill	S 516
Type of Legislation	Senate Bill
Congress	116
Source	View original on Congress.gov

Geographic Scope

National

Description

Prescription Drug Monitoring Act of 2019

This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours.

The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.

Bill Title

Prescription Drug Monitoring Act of 2019

Linked Goals

• Goal:Promote General Welfare

Steps

• 2019-02-14: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
• 2019-02-14: Introduced in Senate

Projected Outcome

A more informed proposal or public response aligned with the Promote General Welfare goal.